2025 年 3 月 19 日- 上午 8:05
圣地亚哥，2025 年 3 月 19 日（GLOBE NEWSWIRE）-- Organovo Holdings, Inc.（纳斯达克：ONVO），一家专注于开发炎症性肠病（IBD）新治疗方法的临床阶段生物技术公司，今天宣布将于 2025 年 3 月 20 日下午 5:00（东部时间）实施 1 股换 12 股的反向股票拆分。Organovo 的普通股将于 2025 年 3 月 21 日星期五市场开盘时以调整后的反向股票拆分基础开始交易。
反向股票拆分后，Organovo 的普通股将继续在纳斯达克资本市场以 “ONVO” 符号交易，新的 CUSIP 号码为 68620A302。
在反向股票拆分生效时，Organovo 已发行和流通的每 12 股普通股将自动转换为 1 股已发行和流通的普通股，面值保持不变，为每股 0.001 美元。这将使已发行和流通的普通股数量从约 2140 万股减少到约 180 万股。反向股票拆分不会改变 Organovo 普通股的授权股数。与反向股票拆分相关的不会发行任何零碎股份，原本有权获得零碎股份的股东将收到现金支付，金额等于该零碎股份乘以 2025 年 3 月 19 日在纳斯达克资本市场上报告的 Organovo 普通股的收盘价格。
此外，Organovo 的股权激励计划下可发行的普通股数量将按反向股票拆分比例进行相应调整，从而使受此类计划约束的股份数量减少。
在 2024 年 11 月 20 日举行的 Organovo 年度股东大会上，Organovo 的股东批准了反向股票拆分，并授予 Organovo 董事会选择反向股票拆分比例的自由裁量权，范围从 1 股换 5 股到 1 股换 20 股。Organovo 董事会于 2025 年 3 月 6 日批准了 1 股换 12 股的反向股票拆分。反向股票拆分旨在使 Organovo 重新符合纳斯达克资本市场继续上市的每股最低出价要求 1.00 美元。
Organovo 的过户代理人，Continental Stock Transfer &amp; Trust Company，将向股东提供有关反向拆分后其股票所有权的信息，以及零碎股份现金支付（如适用）。以账面形式持有股份或通过银行、经纪人或其他代理人持有股份的股东无需采取任何与反向股票拆分相关的行动。他们的账户将自动调整以反映所持股份数量。受益持有人被鼓励与其银行、经纪人或其他代理人联系以获取任何程序性问题的解答。
关于 Organovo Organovo 是一家临床阶段生物技术公司，正在开发在三维（3D）人类组织中有效的药物，作为药物开发的候选者。该公司拥有用于构建模拟人类组织的 3D 技术，能够模仿原生人类组织的组成、结构、功能和疾病的关键方面。有关更多信息，请访问 Organovo 的网站 www.organovo.com。
前瞻性声明 本新闻稿中包含的任何不描述历史事实的声明均构成前瞻性声明，符合 1995 年《私人证券诉讼改革法》的定义。此处包含的任何前瞻性声明均基于当前预期，但受到多种风险和不确定性的影响。这些风险和不确定性以及其他因素在公司向 SEC 提交的文件中进行了更详细的识别和描述，包括其于 2024 年 5 月 31 日提交的 10-K 表格年度报告，以及其于 2025 年 2 月 19 日提交的最新 10-Q 表格季度报告中更新的风险因素。您不应对这些前瞻性声明过于依赖，这些声明仅在作出之日有效。这些警示性声明应与公司未来可能发布的任何书面或口头前瞻性声明一起考虑。除非适用法律（包括美国证券法）要求，否则公司不打算更新任何前瞻性声明，以使这些声明与实际结果、后续事件或情况相符，或反映意外事件的发生。
联系方式：
投资者关系
info@organovo.com
来源：Organovo, Inc.
<img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RNNU5qZzVNU00yT0RFek1ERTVJekl3TWpBd09EVT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RNNU5qZzVNU00yT0RFek1ERTVJekl3TWpBd09EVT0"/>
<img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MDIyNmQ0MTktYThmYi00YzkxLWE3NGEtNWViOGQ4NjgwNzQ3LTEwMzE2NTctMjAyNS0wMy0xOS1lbg==/tiny/Organovo-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MDIyNmQ0MTktYThmYi00YzkxLWE3NGEtNWViOGQ4NjgwNzQ3LTEwMzE2NTctMjAyNS0wMy0xOS1lbg==/tiny/Organovo-Inc-.png"/>

Organovo控股

VIVS

Organovo 控股公司宣布将于 2025 年 3 月 20 日实施 1 股换 12 股的反向股票拆分，以符合纳斯达克每股最低报价要求 1.00 美元。这将使流通在外的股份数量从约 2140 万减少到约 180 万。普通股将继续以 “ONVO” 符号在拆分调整后的基础上进行交易，交易将于 2025 年 3 月 21 日开始。股东将获得任何零碎股份的现金补偿，反向拆分已在 2024 年 11 月 20 日的年度会议上获得股东批准

03/19/2025 - 08:05 AM
<div class="lb-trans">2025 年 3 月 19 日- 上午 8:05
</div>SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD), today announced that it will effect a 1-for-12 reverse stock split of its issued and outstanding common stock that will become effective at 5:00 p.m. Eastern Time on Thursday, March 20, 2025. Organovo’s common stock will commence trading on a reverse stock split-adjusted basis at the opening of the market on Friday, March 21, 2025.
<div class="lb-trans">圣地亚哥，2025 年 3 月 19 日（GLOBE NEWSWIRE）-- Organovo Holdings, Inc.（纳斯达克：ONVO），一家专注于开发炎症性肠病（IBD）新治疗方法的临床阶段生物技术公司，今天宣布将于 2025 年 3 月 20 日下午 5:00（东部时间）实施 1 股换 12 股的反向股票拆分。Organovo 的普通股将于 2025 年 3 月 21 日星期五市场开盘时以调整后的反向股票拆分基础开始交易。
</div>Following the reverse stock split, Organovo’s common stock will continue to trade on the Nasdaq Capital Market under the symbol “ONVO” with a new CUSIP number of 68620A302.
<div class="lb-trans">反向股票拆分后，Organovo 的普通股将继续在纳斯达克资本市场以 “ONVO” 符号交易，新的 CUSIP 号码为 68620A302。
</div>At the effective time of the reverse stock split, every twelve (12) shares of Organovo’s issued and outstanding common stock will be automatically converted into one (1) issued and outstanding share of common stock without any change in the par value of $0.001 per share. This will reduce the number of issued and outstanding shares of common stock from approximately 21.4 million to approximately 1.8 million. The reverse stock split will not change the authorized number of shares of Organovo’s common stock. No fractional shares will be issued in connection with the reverse stock split, and stockholders that would otherwise be entitled to a fractional share will instead receive a cash payment in lieu thereof equal to such fraction multiplied by the closing sales price of Organovo’s common stock as reported on the Nasdaq Capital Market on March 19, 2025.
<div class="lb-trans">在反向股票拆分生效时，Organovo 已发行和流通的每 12 股普通股将自动转换为 1 股已发行和流通的普通股，面值保持不变，为每股 0.001 美元。这将使已发行和流通的普通股数量从约 2140 万股减少到约 180 万股。反向股票拆分不会改变 Organovo 普通股的授权股数。与反向股票拆分相关的不会发行任何零碎股份，原本有权获得零碎股份的股东将收到现金支付，金额等于该零碎股份乘以 2025 年 3 月 19 日在纳斯达克资本市场上报告的 Organovo 普通股的收盘价格。
</div>Furthermore, the number of shares of common stock available for issuance under Organovo’s equity incentive plans will be proportionately adjusted for the reverse stock split ratio, such that fewer shares will be subject to such plans.
<div class="lb-trans">此外，Organovo 的股权激励计划下可发行的普通股数量将按反向股票拆分比例进行相应调整，从而使受此类计划约束的股份数量减少。
</div>At Organovo’s annual meeting of stockholders held on November 20, 2024, Organovo’s stockholders approved the reverse stock split and gave Organovo’s board of directors’ discretionary authority to select a ratio for the reverse stock split ranging from 1-for-5 shares to 1-for-20 shares. Organovo’s board of directors approved the reverse stock split at a ratio of 1-for-12 on March 6, 2025. The reverse stock split is intended for Organovo to regain compliance with the minimum bid price requirement of $1.00 per share of common stock for continued listing on the Nasdaq Capital Market.
<div class="lb-trans">在 2024 年 11 月 20 日举行的 Organovo 年度股东大会上，Organovo 的股东批准了反向股票拆分，并授予 Organovo 董事会选择反向股票拆分比例的自由裁量权，范围从 1 股换 5 股到 1 股换 20 股。Organovo 董事会于 2025 年 3 月 6 日批准了 1 股换 12 股的反向股票拆分。反向股票拆分旨在使 Organovo 重新符合纳斯达克资本市场继续上市的每股最低出价要求 1.00 美元。
</div>Organovo’s transfer agent, Continental Stock Transfer &amp; Trust Company, will provide information to stockholders regarding their stock ownership following the reverse split and cash in lieu of fractional share payments, if applicable. Stockholders holding their shares in book-entry form or through a bank, broker or other nominee do not need to take any action in connection with the reverse stock split. Their accounts will be automatically adjusted to reflect the number of shares owned. Beneficial holders are encouraged to contact their bank, broker or other nominee with any procedural questions.
<div class="lb-trans">Organovo 的过户代理人，Continental Stock Transfer &amp; Trust Company，将向股东提供有关反向拆分后其股票所有权的信息，以及零碎股份现金支付（如适用）。以账面形式持有股份或通过银行、经纪人或其他代理人持有股份的股东无需采取任何与反向股票拆分相关的行动。他们的账户将自动调整以反映所持股份数量。受益持有人被鼓励与其银行、经纪人或其他代理人联系以获取任何程序性问题的解答。
</div>About Organovo Organovo is a clinical stage biotechnology company that is developing drugs that are demonstrated to be effective in three-dimensional (3D) human tissues as candidates for drug development. The company has proprietary technology used to build 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. For more information visit Organovo's website at www.organovo.com.
<div class="lb-trans">关于 Organovo Organovo 是一家临床阶段生物技术公司，正在开发在三维（3D）人类组织中有效的药物，作为药物开发的候选者。该公司拥有用于构建模拟人类组织的 3D 技术，能够模仿原生人类组织的组成、结构、功能和疾病的关键方面。有关更多信息，请访问 Organovo 的网站 www.organovo.com。
</div>Forward-looking Statements Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. These risks and uncertainties and other factors are identified and described in more detail in the Company’s filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on May 31, 2024, as such risk factors are updated in its most recently filed Quarterly Report on Form 10-Q filed with the SEC on February 19, 2025. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events, or circumstances or to reflect the occurrence of unanticipated events.
<div class="lb-trans">前瞻性声明 本新闻稿中包含的任何不描述历史事实的声明均构成前瞻性声明，符合 1995 年《私人证券诉讼改革法》的定义。此处包含的任何前瞻性声明均基于当前预期，但受到多种风险和不确定性的影响。这些风险和不确定性以及其他因素在公司向 SEC 提交的文件中进行了更详细的识别和描述，包括其于 2024 年 5 月 31 日提交的 10-K 表格年度报告，以及其于 2025 年 2 月 19 日提交的最新 10-Q 表格季度报告中更新的风险因素。您不应对这些前瞻性声明过于依赖，这些声明仅在作出之日有效。这些警示性声明应与公司未来可能发布的任何书面或口头前瞻性声明一起考虑。除非适用法律（包括美国证券法）要求，否则公司不打算更新任何前瞻性声明，以使这些声明与实际结果、后续事件或情况相符，或反映意外事件的发生。
</div>Contacts:
<div class="lb-trans">联系方式：
</div>Investor Relations
<div class="lb-trans">投资者关系
</div>info@organovo.com
<div class="lb-trans">info@organovo.com
</div>Source: Organovo, Inc.
<div class="lb-trans">来源：Organovo, Inc.
</div><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RNNU5qZzVNU00yT0RFek1ERTVJekl3TWpBd09EVT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTM5Njg5MSM2ODEzMDE5IzIwMjAwODU="/>
<img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MDIyNmQ0MTktYThmYi00YzkxLWE3NGEtNWViOGQ4NjgwNzQ3LTEwMzE2NTctMjAyNS0wMy0xOS1lbg==/tiny/Organovo-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/MDIyNmQ0MTktYThmYi00YzkxLWE3NGEtNWViOGQ4NjgwNzQ3LTEwMzE2NTctMjAyNS0wMy0xOS1lbg==/tiny/Organovo-Inc-.png"/>

Organovo 宣布进行反向股票拆分 | ONVO 股票新闻